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T cells develop into two major populations distinguished by their T cell receptor (TCR) chains. Cells with the αβ TCR generally
expressCD4orCD8lineagemarkersand mostlyfallintohelper orcytotoxic/eﬀector subsets.Cellsexpressingthealternate γδ TCR
in humans generally do not express lineage markers, do not require MHC for antigen presentation, and recognize nonpeptidic
antigens. We are interested in the dominant Vγ2Vδ2+ T cell subset in human peripheral blood and the control of eﬀector function
in this population. We review the literature on γδ T cell generation and repertoire selection, along with recent work on CD56
expression and deﬁning a cytotoxic/eﬀector lineage within the phosphoantigen-reactive Vγ2Vδ2 cells. A unique mechanism
for MHC-independent repertoire selection is linked to the control of eﬀector function that is vital to the role for γδ Tc e l l s
in tumor surveillance. Better understanding of these mechanisms will improve our ability to exploit this population for tumor
immunotherapy.
1.Introduction
The idea of using the immune system to combat cancer dates
back to 1890, when Paul Ehrlich proposed vaccines against
cancer in the wake of various successful immunizations
to protect against microbial diseases. The importance of
immune surveillance against tumor emergence and pro-
gression was reinforced with the observation that immune
deﬁciency states, including iatrogenic immune suppression,
severe combined immunodeﬁciency (SCID), common vari-
able immunodeﬁciency (CVID), and acquired immunod-
eﬁciency syndrome (AIDS), greatly increased patient sus-
ceptibility to many types of malignancies [1–4]. Targeting
the immune system to combat tumors is in principle, a
promising therapeutic strategy [5] although progress has
been slow and success is limited. Malignant cells are often
diﬃcult to distinguish from normal cells making it diﬃcult
to achieve acceptable therapies and there are few schemes
for generating immune treatments with suﬃcient potency to
overcome the tumor burden.
The recent discovery of tumor associated antigens,
expressed at higher levels or uniquely expressed by tumors
cells, provided a means for targeting immune responses to
speciﬁc malignancies [5, 6]. Eﬀorts have focused on gen-
erating major histocompatibility (MHC)-restricted, tumor
speciﬁc αβ T cells, through vaccination, ex vivo activation
or expansion of cytotoxic lymphocytes, or various methods
of redirected cytolysis. The eﬃcacy of T cell immunother-
apies continues to be limited because tumor neoantigens
are usually weak immunogens except in some cases of
viral transformation where virus antigens are expressed on
malignant cells. Further, MHC tumor-associated antigens
or costimulatory molecules can be downregulated to evade
detectionandtumorscankillorinactivaterespondingTcells
[7–9].
Alternatives to conventional T cell responses might
include the useofinnate-like lymphocytes, suchas γδ Tcells,
which have non-MHC restricted recognition of tumor cells.
The γδ T cell population was ﬁrst described in 1986 with
reports of a new heterodimeric T cell receptor [10] that was2 Clinical and Developmental Immunology
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Figure 1: T Cell Development. γδ T cells most often arise
from the CD4−CD8− (double negative, DN) stages of thymocyte
development as a result of successful rearrangements of both the
γ and δ TCR chains. Little, if any, proliferation occurs between
these steps, thus limiting diversity. Signals delivered in trans from
the CD4+CD8+ (double positive, DP) population is crucial for the
development of eﬀe c t o rf u n c t i o n si nγδ cells. Figure adapted from
Hayday and Pennington [18].
associated with CD3 [11]. Rapid growth and evolution of
this ﬁeld lead to the identiﬁcation of important roles for γδ
T cells in immune regulation, response to infectious disease,
and participation in tumor surveillance. A large and growing
interest centers on the possibility of exploiting γδ Tc e l l s
f o rc a n c e ri m m u n o t h e r a p y[ 12–17]. However, key questions
about the activation and cytotoxic activities of these cells
remain unanswered, especially regarding the mechanisms
controlling cytotoxic eﬀector activities that are limited to a
subset or lineage of cells found in adult human beings.
2. γδ TCellDevelopment
Most of our knowledge about T cell development and espe-
cially about the evolution of cytotoxic γδ T cells comes from
murine studies. T cells develop normally from pluripotent
precursor cells in the thymus. A complex series of signaling
events direct developing thymocytes to become either αβ or
γδ T cells (Figure 1). Most progenitors entering the thymus,
ﬁrst from fetal liver and later from bone marrow, are “double
negative” (DN) expressing neither CD4 nor CD8, the lineage
markers of αβ T cells [19, 20]. Thymocytes progress through
at least 4 DN stages [21, 22]. Murine γδ T cells emerge
mostly from the DN2 and DN3 stages, consistent with their
predominantly CD4−CD8− phenotype in the periphery.
This is also true for humans, though some plasticity remains
even late into αβ diﬀerentiation [23].
Somatic rearrangement of genes encoding the TCR
chains δ, γ,a n dβ begins in DN2 [24]. Several lines of
evidence suggest the Tcrd locus (encoding the δ TCR
chain) rearranges before other TCR genes. In SCID mice,
T cell development is arrested just after recombination
at Tcrd [25]. In humans, the earliest thymic progenitors
(CD34+CD1a−) have a rearranged Tcrd locus, while the
Tcrb locus remains in germline conﬁguration [26]. Addi-
tionally, partial allelic exclusion is evident at the Tcrg locus
[27], indicating that γ chains are pairing with preexisting δ
chains.
Successful recombination of δ and γ chains leads to
expression of γδ TCR on the cell surface. Here, signaling
events through the γδ TCR are thought to drive the
developing thymocytes away from the CD4+CD8+ “double
positive” (DP) stage of αβ maturation and onto the γδ
track. Successful rearrangement of the TCR β chain allows
pairing of the β chain with a surrogate pre-TCRα chain,
formingthepre-TCR.Signaling throughthis pre-TCRallows
survival, extensive proliferation, and diﬀerentiation towards
the DP stage of αβ development, followed by rearrangement
of the Tcra locus [18]. Great diversity is generated in the αβ
population by expansion of pre-TCR expressing cells since
multiple daughter cells, bearing identical β chains, will then
rearrange unique α chains and expand repertoire.
There is no evidence for a pre-TCR in γδ Tc e l l
development[28],indicatingthatcommitmenttotheγδ fate
requires a complete TCR with γ and δ chains successfully
rearranged and paired. Little proliferation occurs during γ
and δ chain rearrangement [28]. The requirement for two
successful recombination events before γδ TCR expression
biases thymocytes towards a αβ T cell fate since only the
β chain needs to be rearranged before expansion of the
population, and limits diversity of the γδ population [29].
In αβ T cells, negative selection prevents autoimmu-
nity by deleting or inactivating cells that express a self-
reactive TCR. Selection is accomplished when self ligands are
expressed by medullary thymic epithelial cells [30]. For γδ
T cells, the criteria for negative selection are poorly deﬁned.
Many of the known γδ T cell antigens in both humans
and mice are self or ubiquitous molecules, making negative
selection for these cells more complex perhaps using subtle
diﬀerences in the strength of signal delivered through the
TCR/CD3 complex.
Positive selection in αβ T cells restricts the TCR reper-
toire by selecting for cells that recognize MHC class I
or II molecules. Selection also deﬁnes lineage, marked by
expression of CD4 or CD8, depending on whether MHC
Class I or II molecules are recognized by the αβ TCR
[31]. Cells recognizing MHC class I downregulate expression
of CD4, become single positive for CD8, and evolve as
cytolytic eﬀectors. Those cells recognizing MHC class II will
downregulate expression of CD8, become single positive for
CD4, and adopt cytokine-secreting helper functions [32].
Additional signals, received either during development or
upon activation, push αβ T cells down other paths including
Th1, Th2, Th17, and regulatory lineages, each with distinct
functions.
For γδ T cells, evidence suggests that signaling through
the expressed TCR is important for commitment to the γδ
lineage, but whether this is accomplished through ligand-
dependent or independent signaling is unknown [18].
Thymic signals may also aﬀect function. It was discovered
recently that a nonclassical MHC molecule T10/T22 binds
directly to mouse γδ T cell heterodimers mainly in the CDR3
region [33–35]. Mice lacking expression of T10 or T22
develop normal numbers of γδ T cells able to recognize these
ligands, suggesting that ligand-dependent selection may notClinical and Developmental Immunology 3
be required for diﬀerentiation [36]. While the number of γδ
Tcellsremained unchanged in T10/T22 knock-outs, thecells
arealteredfunctionally.Thosethatdevelopedinthepresence
of T10/T22 secreted IFN-γ upon activation, while those that
developed without antigen secreted IL-17 [36]. Another
example of the importance for thymic signaling is seen in
the FvB·Tac strain of mice, where the epidermal Vγ5Vδ1
TCR repertoire is depleted [37]. The FvB strain defect has
been mapped as a mutation in the SkinT gene. SkinT is
an Ig superfamily member that encodes a protein in the
butyrophilin family. This protein positively selects epidermal
γδ Tcells;aselectiondoesnotoccurinthemutantFvBstrain
and the repertoire has a lower frequency of Vγ5Vδ1+ cells
[38].
In transconditioning [39–41], the functions of γδ Tc e l l s
are partly dependent on the presence of αβ double positive
(DP, CD4+CD8+) T cells in the thymus. Mice either lacking
the Tcrb gene locus or unable to make the pre-TCRα have
few double positive αβ cells present in the thymus. γδ T
cells arising in these mice show altered gene expression
proﬁles [41]. Activated splenic γδ T cells in these mice adopt
a regulatory phenotype, resembling skin-resident γδ cells
rather than the usual cytotoxic, IFN-γ producing eﬀector
phenotype [40]. Since neither γδ T cells nor DN2 cells have
a cell-autonomous requirement for TCR β, these eﬀects are
thought to be in trans [41].
In 2009, Ribot et al. reported that developing γδ Tc e l l s
in mice could be separated into populations based upon
CD27 expression [42]; diﬀerences were apparent even at
early stages of embryonic development (days 14-15). CD27+
γδ T cells that engaged the ligand CD70 became eﬀector
cells able to secrete IFN-γ. Cells that did not express CD27
developed a regulatory phenotype and secreted IL-17. These
data suggested that distinct lineages exist among γδ T cells,
not unlike CD8 and CD4 αβ T cells, and lineage diﬀerences
impact eﬀector functions.
Overall, evidence suggests that signals received in the
thymus can alter the function of developing γδ Tc e l l si n
mice,eitherthroughtheexpressedTCRorthroughtranscon-
ditioning events. Much less is known about the distinct
developmental stages and unique signaling requirements for
human γδ T cells and CD27 expression was noted [43]
in cytotoxic and noncytotoxic subpopulations of Vγ2Vδ2+
cells, indicating it may not be a strict marker for cytotoxic
subsets in man.
3. Vγ2Vδ2TC ell s
Human γδ T cells can be subdivided into two main
populations based upon δ chain expression. γδ Tc e l l s
expressing the Vδ1c h a i na r em o s to f t e nf o u n di nm u c o s a l
tissues, where they are thought to be involved in maintaining
epithelial tissue integrity in the face of damage, infection, or
transformation [44, 45]. A second population of γδ Tc e l l s
expresses the Vδ2 chain and makes up about 1%–10% of
circulating lymphocytes in healthy human adults [46]. The
Vδ2 chain pairs almost exclusively with Vγ2 (called Vγ9i n
an alternative nomenclature). The Vγ2Vδ2 pairing is only
present in humans and nonhuman primates [44, 47].
γδ T cells are often termed innate-like lymphocytes,
due to their rapid, antigen-triggered responses, and lack
of classical MHC restriction. However, they possess a TCR
composed of rearranging germline elements [46], require
antigen presentation [48], and undergo peripheral selection
[49], arguing they should be classiﬁed as components of
adaptiveimmunity.Functionally,theydemonstratecytotoxic
responses against cells infected with a variety of viruses,
bacteria, or protozoa and they also recognize and kill
many human tumors [44, 50]. Cytotoxicity is mediated in
much the same manner as for αβ T cells, namely, through
perforin/granzyme and Fas/FasL pathways or the production
of TNF-α [51, 52].
γδ T cells are preserved evolutionarily in all jawed
vertebrates [53] indicating that their role in immune defense
is not redundant [44]. Indeed, the αβ and γδ Tc e l l
populations recognize vastly diﬀerent types of antigens. αβ
T cells recognize nonself peptide fragments presented by
MHC molecules. γδ T cells, on the other hand, recognize
a wide variety of self-antigens including stress molecules
like MICA and MICB, heat shock proteins, and intriguingly,
nonpeptidic metabolites of isoprenoid biosynthesis [54–58].
Theydo not requireconventional antigen presentationin the
context of MHC [59].
The diﬀerences in antigen recognition and speciﬁcities
between the two T cell types deﬁne their unique roles in
immunity. Studies using both αβ and γδ T cell-depleted
mice showed qualitative and quantitative diﬀerences in
clearance of infections [60, 61]. Human patients with
microbial diseases, such as tuberculosis or malaria, often
have large expansions of the peripheral γδ T cell subset,
sometimes comprising up to 80% of all T cells [62–64].
In the case of malaria, these expanded cells are believed to
mediate pathogen elimination. Some viral infections, such as
Hepatitis C Virus and Coxsackie B, induce high numbers of
γδ T cells that home to the site of infection and contribute
to pathology [50, 65]. Human Immunodeﬁciency Virus type
1 (HIV-1) infection results in rapid and speciﬁc depletion
of the peripheral Vδ2 T cell population with consequences
for the host’s ability to resist intercurrent infections [66, 67].
Interestingly, γδ T cell levels and activity are high among
patients who have natural control of HIV without the use
of antiretroviral therapy [68]. These unique protective or
pathogenic responses of γδ T cells in diverse infectious
diseases highlight their unique roles in immunity.
The γ and δ TCR chains share an Ig-like structure similar
to the αβ T cell receptor; chain expression is determined
by randomly rearranging V, (D) and J segments. In the
case of γ and δ chains, the germline repertoire is restricted
severely, due to a limited number of rearranging elements
[69]. For instance, the Tcrb locus has 48 functional V and
13 functional J elements, compared to the 8 V and 5 J
elements of the Tcrg locus [70]. Much of the CDR3 region
diversity is due to N nucleotide addition at the V-J and V-D-J
junctions [46]. Due to multiple D segment rearrangements
in the δ chain, actual diversity may be even greater than
that seen in αβ T cells [71, 72]. Despite the potential
for diversity, greater than 60% of circulating γδ Tc e l l s
bear the Vγ2Vδ2T C R[ 73, 74], suggesting either restricted4 Clinical and Developmental Immunology
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Figure 2: Human Vγ2Vδ2 T cells respond to stimulatory phosphoantigens produced during bacterial or mammalian isoprenoid synthesis.
Isoprenoid synthesis in many prokaryotes and protists produces the intermediate (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate
(HMBPP) from pyruvate and glyceraldehyde 3-phosphate via the erythritol 4 phosphate pathway. Eukaryotes use the mevalonate pathway
that produces isoprenoids and colesterol. HMBPP and IPP are phosphoantigens; HMBPP is unique to the erythritol 4 phosphate pathway
while IPP is produced in both pathways. Phosphoantigens stimulate cytokine secretion and cytotoxicity in human Vγ2Vδ2 T cells. Statins
block the eukaryotic pathway prior to mevalonate synthesis, and decrease the production of IPP. Bisphosphonates are a class of drugs that
inhibit farnesyl pyrophosphate synthase and cause the accumulation of IPP in mammalian cells. When mammalian cells of myeloid origin
and some tumor cells are treated with bisphosphonate, they are more stimulatory for Vγ2Vδ2 T cells due to increased IPP production.
chain pairing or a selective chronic expansion of this cell
population. Studies comparing the genotypes of γδ clones
derived from the thymus with those derived from peripheral
blood found that thymic clones possessed nearly all possible
Vγ-Vδ combinations, with the Vγ2Vδ2 pairing making up
only 5%, indicating that physical restriction on chain pairing
was not a critical factor [46]. Nearly all peripheral γδ Tc e l l s
acquire memory markers by the time an individual reaches
2y e a r so fa g e[ 75, 76]. These data suggest that selective
activation and expansion in response to ubiquitous or self-
antigensisthemechanismresponsibleforoverrepresentation
of the Vγ2Vδ2 T cell subset among adults [71, 77].
Vγ2Vδ2 T cells respond to low-molecular weight, non-
peptidic, phosphate-containing molecules termed phospho-
antigens [78, 79]. The best characterized of these antigens
is isopentenyl pyrophosphate (IPP) [54], a substrate in the
mevalonate pathway for cholesterol synthesis (Figure 2)i n
eukaryotes and some bacteria [80]. Physiologic levels of IPP,
however, are not stimulatory [81]. A more potent antigen
is (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate, or
HMBPP [82], a substrate in the nonmevalonate pathway
found in plants and prokaryotic organisms [83, 84]. The
diﬀerence in potency is thought to provide a mechanism for
self-recognition, wherein γδ T cells respond to local bacterial
infections, but not to normal tissues [85].
Phosphoantigen stimulation causes a polyclonal expan-
sion of Vγ2Vδ2 T cells and selects for the Vγ2-Jγ1.2
rearrangement but does not select speciﬁc complementary
determining region 3 sequences (CDR3). Spectratyping
analysisoftheVγ2chaindemonstratedastrongbiasforVγ2-
Jγ1.2 rearrangements, reﬂecting chronic expansion of the
population in response to phosphoantigens. Spectratyping
of the Vδ2 chain, on the other hand, showed a normal
distribution of chain lengths [86], suggesting less bias in
the Vδ2 chain repertoire and arguing that phosphoantigen
recognition is inﬂuenced mainly by Vγ chain sequences.
X-ray crystal structures of a human Vγ2Jγ1.2 Vδ2T
cell receptor revealed a potential positively charged binding
pocket made of arginine residues from the Vγ2s e g m e n t
and lysine residues from the Jγ1.2 segment, of which Lys109
appeared to be most important [70]. Site-directed muta-
genesis conﬁrmed the importance of these lysine residues,
as mutations in the KKIK amino acid stretch encoded in
Jγ1.2 either partially or completely abolished responsiveness
to phosphoantigens [87]. No particular rearrangements were
selectedin the δ chain [86], though a conserved hydrophobic
residue at position 97 was correlated with antigen recogni-
tion [88]. Perhaps the most compelling argument for TCR
interactions with phosphoantigen is that transfection of the
Vγ2-Jγ1.2Vδ2 TCR into a TCR negative JRT3 T cell line
conferred responsiveness to phosphoantigen [89].
DespiteevidenceimplicatingtheVγ2Jγ1.2chaininphos-
phoantigen reactivity, all attempts to show physical interac-
tions between receptor and antigen have been unsuccessful
[59]. While neither phosphoantigen-driven activation nor
the cytotoxic activity of γδ T cells requires MHC molecules,
activation does depend upon cell-cell contact with an
antigen presenting cell (APC) [48, 90]. Stimulated γδ Tc e l l s
themselves seem to act as APC, but self-activation is not
optimal for proliferation responses [91]. Antigen processing
by APC is not required; paraformaldehyde-ﬁxed cells are still
able to stimulate γδ T cell responses [90]. This suggests that
an antigen presentation molecule is involved in TCR recog-
nition of phosphoantigen. In fact, tetramers of murine γδ
TCR bind to cells in an antigen-dependent manner [34]a n d
similar data are emerging for human Vγ2Vδ2T C R[ 92, 93].Clinical and Developmental Immunology 5
4. γδ Recognition of Tumor Cells
In addition to their defensive role in microbial infections,
γδ T cells are cytotoxic against a variety of tumor cell lines
including B cell lymphomas, multiple myeloma, and solid
tumors of the kidneys, colon, prostate, breast and head
and neck [94–97]. Attempts to deﬁne a speciﬁc antigen
among this diverse group of malignancies have pointed
to overproduction of metabolic intermediates like IPP, by
transformed cells [98]. Repertoire analysis of γδ Tc e l l s
expanded by exposure to IPP or Daudi cells demonstrated
very similar Vγ2 chain repertoire, indicating a substantial
overlap of phosphoantigen and tumor cell recognition [99].
Furthermore, bisphosphonates, a class of drugs used to
treat certain bone diseases, inhibit farnesyl synthase in the
mevalonate pathway, lead to overproduction of IPP [100],
and these drugs also stimulate γδ Tc e l lp r o l i f e r a t i o ni n
PBMC cultures. Patients taking these drugs often show
signiﬁcantexpansionsoftheVγ2Vδ2pe rip he ralTc ells ubset
[14, 101].
Not all evidence supports the idea of IPP as a tumor
antigen. While all tumors have increased metabolic activity
and would therefore produce increased metabolic inter-
m e d i a t e ss u c ha sI P P ,n o ta l lt u m o r ss t i m u l a t eV γ2Vδ2
T cells [99]. γδ tumor responses are also species speciﬁc,
despite the fact that tumors from mice or other species will
have increased metabolic activity and also produce excess
IPP [102]. Moreover, it is not certain that ﬁnely tuned
tumor surveillance could be accomplished by recognizing
an ubiquitous, metabolic intermediate. Freshly isolated γδ T
cells demonstrate little to no basal cytolytic activity against
most tumor cell lines; ex vivo expansion in response to
phosphoantigenstimulationisneededtogeneratebroadlytic
activity [103, 104]. All of these data imply that the γδ TCR is
important for recognizing phosphoantigen and proliferating
in response to antigen, but its mechanism for discriminating
transformed from normal tissues remains unclear.
Given the conﬂicting evidence for IPP as tumor antigen,
an extensive search for conclusive Vγ2Vδ2 antigens has
been underway. Comparing cell surface markers expressed
on tumor cell lines susceptible to γδ Tc e l ll y s i sw i t h
those expressed by resistant tumor cell lines suggested
that a structure related to the mitochondrial ATP-synthase
molecule may be an antigen [105] The F1-ATPase bound
directly to the Vγ2Vδ2 TCR, as shown by surface plasmon
resonance, and binding induced IFN-γ and TNF-α release
from clones. Apolipoprotein A that binds both the TCR
and the ATPase [105], enhanced cell activation. While this
study provided the ﬁrst physical evidence for TCR binding
to another molecule, the signiﬁcance of these interactions
is unknown. Additionally, blocking of the ATPase by a
monoclonal antibody reduced speciﬁc tumor cell lysis by γδ
T cells but did not abolish it, suggesting a role for other
cell:cell interactions.
Gene transfer studies demonstrated the dependence of
phosphoantigen recognition on the Vγ2Vδ2T C R ,a sm e n -
tioned previously. However, when this system was used to
analyze activation by Daudi lymphoma cells, a much weaker
response was generated [89]. Studies using Daudi cells fused
with melanoma or lymphoma cell lines, resulted in a signiﬁ-
cant depression of Vγ2Vδ2 T cell expansion and a resistance
to cytotoxicity, presumably due to expression of MHC class I
on the surface of hybrid cells [106]. This suggests a system of
self recognition similar to NK cells. There is conﬂicting evi-
dence regarding antibody blockade of the Vγ2Vδ2T C R .I n
some reports, TCR blocking resulted in a signiﬁcant decrease
in the ability of cells to lyse tumor targets [107, 108]. Others
showed that blocking of the TCR resulted in little or no
decreaseincytolysisagainstavarietyoftumorcelltypes[103,
109], again calling into the question the role for the Vγ2Vδ2
TCR and hinting at the presence of other cytotoxicity-
mediating molecules on the surface of activated γδ T cells.
In addition to the characteristic TCR, γδ T cells also
possess a variety of NK cell receptors including the acti-
vating receptor NKG2D [110], the inhibitory NKG2A, and
killer immunoglobulin-like receptors (KIR) [111, 112]; the
KIR family of receptors can be activating or inhibitory
[113].NKG2DrecognizestheMHC-classI-relatedmolecules
MICA and MICB, as well as the UL-16 binding proteins
(ULBP), all of which are expressed frequently on trans-
formed cells and deliver activating signals [55, 114]. NKG2D
is highly expressed on γδ T cells before and after phos-
phoantigen stimulation. The inhibitory receptors recognize
MHC class I molecules on the surface of normal cells and act
to inhibit cytotoxic responses, making sure they are directed
only against infected or transformed cells. Although γδ T
cells possess many of the same receptors, NK and γδ Tc e l l s
do not lyse all of the same tumor targets [115] implying
unique recognition systems in these two cell types.
It is likely that NK receptors play a role in γδ Tc e llt u m o r
killing [116], but their exact contribution is uncertain and
likely inﬂuenced by the type of tumor target. As mentioned
previously, Daudi cells lack MHC Class I expression on their
surfaceandarehighlysusceptibletoγδ Tc elllysis[117,118].
Cytotoxicity is signiﬁcantly reduced though not abolished,
when Daudi cells are engineered to express MHC [106],
indicating that inhibitory NK or KIR receptors negatively
regulate γδ T cell function. In fact, expression of inhibitory
KIR on γδ T cells correlates with the level of cytotoxicity, a
pattern already known for NK and αβ T cells [112, 119].
Antibody blocking studies directed against the γδ TCR
indicate that some of the tumoricidal activity seen in
expanded cells is TCR-independent [103, 109, 120]. This
ﬁnding, combined with high levels of NKG2D expressed
on expanded γδ cells, suggested that activating NKR has
a major role in tumor cytolysis [120]. Ligation of NKG2D
leads to cytolytic responses, Th1 cytokine secretion, and
release of cytotoxic granules [55, 121]. Lytic activity of
Vγ2Vδ2 cell lines against MICA-expressing targets can be
inhibited by up to 50% when blocked by anti-MICA or
anti-NKG2D monoclonal antibodies [121]. Unstimulated
peripheral blood Vγ2+ cells also express NKR [112] but still
require phosphoantigen stimulation before demonstrating
potent lytic activity [121].
While NKR and other costimulatory molecules are likely
involved in γδ T cell tumor recognition and lysis, cells
possessing the speciﬁc Vγ2Vδ2 TCR are selectively expanded
and maintained in peripheral blood and show the highest6 Clinical and Developmental Immunology
cytotoxicity toward particular tumor targets. This implies a
deﬁnitive role for the TCR, but the control over γδ Tc e l l -
mediated killing remains unclear. The TCR could be the
sole signal required for lytic function or might contribute to
various activating signals received through other receptors
much like NK cells. Alternatively, the TCR could act as
a growth factor receptor, much like the TCR in invariant
NKT cells [122], recognizing a metabolite and mediating
activation of the population without a direct role in tumor
cell recognition.
5.CD56 asaMarker ofCytotoxicity
As discussed previously, developing thymocytes in the
murine system segregated into eﬀector and regulatory γδ T
cell lineages at early embryonic stages with a prominent role
for IL-17 in γδ T cells that are na¨ ıve to antigen [36, 42].
These distinct subsets were preserved even during antigen
stimulation and expansion [42]. In humans, no distinct γδ
T cell thymocyte subsets are known. When mature cells were
expanded with phosphoantigen, potent cytotoxic Vγ2Vδ2
eﬀectors could be distinguished from weakly lytic cells by the
level of CD56 expression [43]. A low proportion (1%–2%)
of adult Vγ 2Vδ2 T cells express IL-17 upon phosphoantigen
stimulation [123] and might have a regulatory role during
responses to infections or tumors. However, little is known
abouttherequirementforγδ Tcell-producedIL-17intumor
cytotoxicity.
CD56,alsoknownas(NCAM),isacalcium-independent
adhesion molecule, discovered originally in the nervous
system [124]. CD56 has been detected on a number of cell
types, most notably NK cells and certain cytotoxic T cells
(including some γδ T cells). CD56 undergoes alternative
splicing to generate multiple isoforms depending on cell
type and stage of development. Both NK and T cells express
exclusively the transmembrane-anchored, 140-kD form
[125]. CD56 expression on cytotoxic lymphocytes correlates
with lack of MHC restriction, reduced TCR dependence
[126], and senescence [127]. The restricted oligoclonal Vβ
repertoire present in the CD56+ αβ lymphocytes and their
memory cell phenotype is consistent with antigen selection
and expansion [128]. CD56 does not appear to play a role
in the killing activity of CTL, although crosslinking of the
moleculedoesinducecellsignalingasevidencedbyincreased
total phosphorylation [129]. In the nervous system, CD56
is involved in cell adhesion through homotypic interactions
between CD56-expressing neurons [130]. Studies examining
CD56 as an adhesion molecule in NK lysis of tumor cells
were inconclusive [129, 131] and the exact function of CD56
in the immune system remains unknown.
Recently, CD56 expression was used as a marker
todivide NKcellsinto highlycytotoxicCD56dimCD16+KIRhi
and weakly cytotoxic, cytokine-producing CD56bright
CD16
−KIRlow populations. Once believed to be a uniform
eﬀector population, it is now thought that NK cells can be
activated and progress along a diﬀerentiation path similar
to T cells, maturing from CD56bright to CD56dim upon
activation [132].
We and others found that CD56 expression marks a
subset of peripheral Vγ2Vδ2 T cells that are potently cyto-
toxic for tumor cells [43, 133]. Following phosphoantigen
expansion, about 50% of peripheral γδ T cells express
CD56 [43]. These cells display potent cytotoxicity against
squamous cell carcinoma of the head and neck (SCCHN)
cell lines among others, and are resistant to FasL-mediated
apoptosis. Expression of CD56 can be induced on CD56
negative fresh γδ T cells after treating with IL-2 or IL-
15 alone but interestingly, these cells do not gain lytic
potential [43] suggesting that stimulation through the TCR
and proliferation are together necessary for gain of cytotoxic
function.
InVγ2Vδ2Tcells,CD56isanunusualactivationmarker.
Its expression is not suﬃcient for cytotoxic activity, since
freshly isolated CD56+ γδ T cells and cells treated with
IL-2 alone are not lytic for tumor cells [43, 104]. After
expansion, CD56 expression is a marker for cytotoxicity.
When Vγ2Vδ2Tcellswereexpandedbyphosphoantigenand
separated into CD56+ and CD56− fractions, we found sharp
diﬀerences in the Vγ2 chain repertoire among these subsets
[134]. Cells in both fractions proliferated rapidly after
phosphoantigen/IL-2 stimulation, but the subset expressing
CD56uniquelypossessedcytolyticactivityagainsttumorcell
targets.PublicVγ2chainsequencescommontomosthealthy
adults were present in CD56+ or CD56− fractions and
their distribution bias was diﬀerent for each donor, arguing
that Vγ2 chains were not selected to be in the CD56+,
cytotoxic subset based on antigen-recognition properties.
Further, the reproducible, biased distribution of clones into
CD56+ or CD56− fractions showed that control of CD56
expression was not random and the marker did not behave
as an activation antigen. The pattern of CD56 expression
seems to deﬁne a lineage within circulating Vγ2Vδ2T
cells. Phosphoantigen triggers proliferation among all cells
expressing the Vγ2Jγ1.2Vδ2 TCR, but only the precursor
CTL, deﬁned by their capacity to express CD56 after activa-
tion, develop cytotoxic eﬀector activities. The mechanisms
controlling lineage, whether this occurs before or after
TCR expression, and whether mature clones can acquire
or lose the capacity to express CD56, all remain as open
questions.
The analysis of CD56 expression and TCR sequences
on Vγ2Vδ2 T cells shows that T cell populations harbor
precursors to cytotoxic and noncytotoxic subsets, and the
CD56+ subset tends to oligoclonality. The picture for γδ T
cells is similar to what was observed previously for CD8+ αβ
T cells [128, 135] where the CD56+ subset was oligoclonal
and required for cytotoxicity. A similar ﬁnding was reported
previously for CD8+ αβ T cells. In that study [128], human
CD8+ αβ T cells were sorted into CD56+ and CD56− frac-
tions before assaying redirected cytotoxicity against murine
P815 cells (FcR+) using anti-CD3 monoclonal antibody.
The CD56+ fractions had higher value for speciﬁc lysis and
tended to oligoclonality be compared with CD56− cells from
the same donors. Thus, CD56 is a marker for both αβ and γδ
CTL, and the trend to oligoclonality suggests these cells have
been selected and maintained. For Vγ2Vδ2 cells, we know
that the Vγ2 chain repertoire is stable for years and possiblyClinical and Developmental Immunology 7
decades in healthy donors [99], with a tendency to become
more oligoclonal over time. Clearly, selection mechanisms
exist to expand and maintain CD56+ subsets and preserve
the capacity for CTL function.
The ﬁnding that CD56 expression is clonally-restricted
but not linked to speciﬁc Vγ2 chains [134] clariﬁes the
mechanism controlling Vγ2Vδ2Tc e l lt u m o rc y t o t o x i c -
ity but does not solve fundamental problems of tumor
cell recognition. Indeed, it is likely that the capacity for
expressing CD56 was adopted at an early stage of γδ T
cell diﬀerentiation. Such a mechanism would be consistent
with our ﬁnding [134] that multiple cells expressing the
same Vγ2 chain nucleotype (indicating that they all derived
from the same original clone) segregate together into
CD56+ or CD56− subsets. Thus, CD56+ clones within the
mature γδ T cell repertoire but are not distinguished by
TCR speciﬁcity. We also know from cell cloning studies
[134] that CD56+ cells are heterogeneous with respect
to KIR expression. These insights are leading to a view
that early lineage marking and heterogeneous expression
of KIR limit the proportion of phosphoantigen-responsive
Vγ2Vδ2+ cells that are capable of tumor cell lysis. In a
sense, we are describing NK tumor cell cytolysis except
that initial cell activation depends on a rearranged TCR
and phosphoantigen recognition. Mature Vγ2Vδ2Tc e l l s
represent between 1/40 and 1/400 of circulating; CD3+ cells
in healthy adults and limitations on the capacity for CTL
function may be necessary to prevent lethal autoimmunity
during γδ responses to infection or malignant transforma-
tion. Virtually all Vγ2Vδ2 cells produce proinﬂammatory
cytokines IFN-γ and TNF-α after stimulation, and this
function also ﬁgures prominently in their immune response
activities.
6. Summary
Human γδ T cells present fascinating challenges to our
understanding of T cell selection, repertoire maintenance,
and the control of eﬀector functions. Because they have
a limited γ chain repertoire in adults and they include a
high proportion of clines responding to a single antigen,
this system permits unique experimental studies not always
possible with αβ T cells. An important example is the
recent discovery of a cytotoxic eﬀector lineage within the
adult population that expresses CD56 and kills tumor cells
upon activation. This γδ Tc e l ll i n e a g eh a ss i m i l a r i t i e st o
CD8+ αβ CTL, but is selected in the absence of lineage
marker (CD8) expression and without conventional MHC
restriction. In ways that are not yet clear, γδ Tc e l l s
(especially the human Vγ2Vδ2+ subset) are selected for
response to self-antigens including isopentenylpyrophos-
phate made by all mammalian cells, without triggering
lethal autoimmunity. This produces a T cell subset poised
for rapid responses to infected or malignant cells. Much
remains to be learned about this interesting subset of T
cells, though it is increasingly clear that γδ T cells are
important for many immune responses and are novel targets
for new for new immunotherapies in cancer and infectious
disease.
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